Register to chat with like-minded investors on our interactive forums.

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next >>

Date	Time	Source	Headline	Symbol	Company
02/09/2023	7:44AM	PR Newswire (US)	AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results	NYSE:ABBV	AbbVie Inc
01/25/2023	11:42AM	PR Newswire (US)	Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023	NYSE:ABBV	AbbVie Inc
01/18/2023	8:00AM	PR Newswire (US)	JUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE	NYSE:ABBV	AbbVie Inc
01/17/2023	8:00AM	PR Newswire (US)	SkinMedica® Launches Even & Correct	NYSE:ABBV	AbbVie Inc
01/16/2023	9:00AM	GlobeNewswire Inc.	Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields	NYSE:ABBV	AbbVie Inc
01/10/2023	8:50AM	Dow Jones News	AbbVie, Anima Biotech to Collaborate on mRNA Biology Modulators	NYSE:ABBV	AbbVie Inc
01/10/2023	8:16AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
01/10/2023	8:00AM	PR Newswire (US)	AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets	NYSE:ABBV	AbbVie Inc
01/09/2023	7:01AM	PR Newswire (Canada)	QULIPTA™ Now Approved by Health Canada for the Preventive Treatment of Episodic Migraine in Adults	NYSE:ABBV	AbbVie Inc
01/09/2023	7:01AM	PR Newswire (Canada)	QULIPTA(MC) est maintenant approuvé par Santé Canada pour la prévention de la migraine épisodique chez les adultes	NYSE:ABBV	AbbVie Inc
01/06/2023	4:16PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
01/06/2023	8:00AM	PR Newswire (US)	AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets	NYSE:ABBV	AbbVie Inc
01/06/2023	8:00AM	Business Wire	AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets	NYSE:ABBV	AbbVie Inc
01/05/2023	8:00AM	PR Newswire (US)	AbbVie to Host Fourth-Quarter 2022 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
01/03/2023	5:07PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
01/03/2023	8:00AM	PR Newswire (US)	AbbVie to Present at the 41st Annual J.P. Morgan Healthcare Conference	NYSE:ABBV	AbbVie Inc
12/16/2022	6:39PM	PR Newswire (US)	U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder	NYSE:ABBV	AbbVie Inc
12/16/2022	7:30AM	PR Newswire (US)	AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age	NYSE:ABBV	AbbVie Inc
12/14/2022	5:06PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
12/12/2022	12:59PM	PR Newswire (US)	AbbVie Named to Dow Jones Sustainability World Index for 10th Straight Year	NYSE:ABBV	AbbVie Inc
12/11/2022	5:30PM	PR Newswire (US)	AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas	NYSE:ABBV	AbbVie Inc
12/10/2022	3:00PM	PR Newswire (US)	AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients	NYSE:ABBV	AbbVie Inc
12/10/2022	11:15AM	PR Newswire (US)	AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science	NYSE:ABBV	AbbVie Inc
12/06/2022	8:00AM	PR Newswire (US)	AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline	NYSE:ABBV	AbbVie Inc
12/06/2022	2:00AM	PR Newswire (US)	AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress	NYSE:ABBV	AbbVie Inc
12/01/2022	7:01AM	PR Newswire (Canada)	AbbVie Announces Provincial Reimbursement for RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan	NYSE:ABBV	AbbVie Inc
12/01/2022	7:01AM	PR Newswire (Canada)	AbbVie annonce le remboursement de RINVOQ® (upadacitinib) pour le traitement de la polyarthrite rhumatoïde et du rhumatisme psoriasique en Alberta, au Nouveau-Brunswick, en Ontario, au Québec et en Saskatchewan	NYSE:ABBV	AbbVie Inc
11/29/2022	9:35AM	TipRanks	BMO Capital Sticks to Its Buy Rating for AbbVie (ABBV)	NYSE:ABBV	AbbVie Inc
11/28/2022	6:01AM	TipRanks	AbbVie’s (NYSE:ABBV) Loss Could be CVS’s (NYSE:CVS) Gain	NYSE:ABBV	AbbVie Inc
11/24/2022	7:01AM	PR Newswire (Canada)	Les conséquences de l'inaction - Une nouvelle publication révèle qu'une partie du Canada n'est pas en voie d'atteindre l'objectif mondial d'élimination de l'hépatite C	NYSE:ABBV	AbbVie Inc

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next >>

Clean Vision (QB)

Elite Pharmaceuticals (QB)

Enzolytics (PK)

ERHC Energy (CE)

Ronn Motor (PK)

Voip Pal Com (QB)

Decentral Life (PK)

Fannie Mae (QB)

Digital Brand Media and ... (PK)

Kraig Biocraft Laborator... (QB)

Bioelectronics (PK)

Delayed Upgrade Clock